Saturday, July 13, 2024

Discovery Research Collaboration Between Evotec and Pfizer to Advance Drug Development in France

Similar articles

Evotec announced a significant multi-year master research collaboration on discovery research, option, and license agreement with Pfizer. This collaborative effort is set to focus initially on early discovery research targeting metabolic and infectious diseases. The research will be conducted at Evotec’s advanced facilities in France, prominently including Campus Curie in Toulouse. This state-of-the-art research site is equipped with cutting-edge capabilities such as high throughput screening, in vitro and in vivo biology, proteomics, and metabolomics. Under the agreement, Evotec will receive research support funding from Pfizer, and the company will be eligible for potential milestones and royalties based on the success of the collaborative programs.

Dr. Matthias Evers, Chief Business Officer at Evotec, expressed his enthusiasm about the partnership: “We are honored to collaborate with Pfizer to explore potential new first-in-class therapeutic approaches. France has established a thriving biopharmaceutical ecosystem to which Evotec significantly contributes, with our strong presence and more than 1,000 employees at our French sites. By focusing on diseases with severe unmet medical needs and leveraging highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D activities.”

Evotec SE is renowned for its unique business model dedicated to discovering and developing highly effective therapeutics and making them available to patients. The company’s multimodality platform combines a unique blend of innovative technologies, data, and science, facilitating the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec partners with all Top 20 Pharma companies, over 800 biotechnology companies, academic institutions, and other healthcare stakeholders, co-creating high-value pipeline partnerships.

Evotec and Pfizer Collaborate on Discovery Research to Tackle Underserved Therapeutic Areas

The company’s strategic activities span a broad range of currently underserved therapeutic areas, including neurology, oncology, metabolic, and infectious diseases. Evotec aims to build the world’s leading co-owned pipeline for innovative therapeutics, with a portfolio comprising more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.

Dr. Luca Mollo, Vice President and Medical Lead France at Pfizer highlighted the importance of this collaboration: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. France has developed a robust biopharmaceutical ecosystem, and we’re excited to build on our shared commitment to advancing scientific discovery for diseases with unmet needs.”

Pfizer, a global leader in pharmaceuticals, is committed to leveraging this collaboration to enhance its drug discovery research capabilities. This partnership with Evotec underscores Pfizer’s dedication to addressing significant medical challenges through innovative research and development.

Discovery Research

Evotec and Pfizer Leverage Advanced Research Infrastructure for Ambitious Drug Discovery Collaboration

The collaboration is expected to capitalize on Evotec’s extensive experience and cutting-edge research infrastructure. Campus Curie in Toulouse, one of the key sites for this research, exemplifies Evotec’s commitment to scientific excellence and innovation. With capabilities spanning high throughput screening, advanced biological research, and comprehensive proteomic and metabolomic analysis, Campus Curie is well-positioned to support the ambitious goals of this collaboration.

Evotec’s strategic activities are aligned with its mission to discover and develop highly effective therapeutics. The company’s global presence, with over 5,000 highly qualified employees, and its synergistic technologies and services in Europe and the USA, enable it to operate as complementary clusters of excellence. This collaboration with Pfizer is poised to make significant strides in the field of drug discovery, particularly in addressing metabolic and infectious diseases.

You can follow our news on our Telegram and LinkedIn accounts.

The announcement of this collaboration comes at a time when the need for innovative therapeutic solutions is more pressing than ever. The combined expertise and resources of Evotec and Pfizer are expected to accelerate the development of novel treatments, ultimately benefiting patients worldwide.

 

Resource: Evotec, July 10, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article